Evidence map›Paper›PMID 32130819›Full record

ArticleThe New England journal of medicine2020

Triumph and Tragedy of 21st Century Tuberculosis Drug Development.

Guy Thwaites, Payam Nahid

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis.American journal of respiratory and critical care medicine · 2023
    Article
  2. Article
  3. Machine Learning Models forMolecular pharmaceutics · 2022
    Article
  4. Article
  5. UNITE4TB: a new consortium for clinical drug and regimen development for TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021
    Article
  6. Article
  7. Molecule Property Analyses of Active Compounds forJournal of medicinal chemistry · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Guy ThwaitesFrom the Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (G.T.); the Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom (G.T.); and the UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco (P.N.).
Payam NahidFrom the Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (G.T.); the Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom (G.T.); and the UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco (P.N.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

IodineTuberculosisTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryDrug DevelopmentHumansIodine

Identifiers

PMID32130819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.